Seeking Alpha: Endo's Bid For Auxilium Makes Sense

Endo International (NASDAQ:ENDP) has been very acquisitive over the past couple of years, using deals to not only leverage its tax-advantaged Irish domicile but bulk up what I believe is an underrated generics business. Tuesday's announcement of an offer to buy Auxilium (NASDAQ:AUXL) makes quite a bit of sense; not only is their potential tax leverage here, but Endo's strong legacy position in urology could improve uptake of Auxilium's key drug Xiaflex and recharge Endo's branded drug business.

Continue reading here:
Endo's Bid For Auxilium Makes Sense

The Motley Fool: Auxilium Pharmaceuticals Inc Joins the Buyout Bonanza

Amidst high-profile deals like Pfizer's pursuit of AstraZeneca, Actavis's acquisition of Forest Labs, and Valeant's (NYSE: VRX  ) pursuit of Allergan, it might be easy to forget that it is not just large companies that can benefit from tax inversion deals that lead to a company reestablishing its headquarters in a lower-tax jurisdiction. Auxilium (NASDAQ: AUXL  ) , a small specialty pharmaceutical company, has thrown its hat into the tax inversion ring with an announced acquisition of Canada's QLT (NASDAQ: QLTI  ) . Investors did not universally cheer the news, though, and it's unclear just how much benefit Auxilium will really see from this move.

Read more here:
Auxilium Pharmaceuticals Inc Joins the Buyout Bonanza

Seeking Alpha: Shedding A Little Light On Under-Followed DUSA Pharmaceuticals

There are certain dusty corners of biopharma where most investors just don't look all that often, and eye care and skin care are high on the list. While the addressable markets are well short of what investors expect from areas like oncology or autoimmune disease, the relative lack of competition can make these profitable niches. As under-followed ISTA Pharmaceuticals (ISTA) recently rode a limited roster of products to a worthwhile takeout price, investors may want to consider DUSA Pharmaceuticals (DUSA) for similar potential.

Read more here:
Shedding A Little Light On Under-Followed DUSA Pahrmaceuticals